Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zealand Pharma, a Danish biopharmaceutical company, has announced that its partner Sanofi has submitted a marketing authorization application (MAA) for Lyxumia (lixisenatide) in Europe.
Subscribe to our email newsletter
Lixisenatide, discovered by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for Type-2 diabetes .
Sanofi is set to complete Phase III development of the drug as a new treatment for the disease.
The MAA includes data from the GetGoal Phase III program, comprising nine studies and over 4,300 patients.
The GetGoal program provides data to support lixisenatide in treating adults with Type-2 diabetes mellitus.